search
Back to results

An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

Primary Purpose

Post Operative Pain

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Percocet
Xartemis
Sponsored by
Lotus Clinical Research, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Operative Pain focused on measuring Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who provide written informed consent prior to enrollment
  • Male or female and 18 years of age or older.
  • Patients who are scheduled to undergo elective general surgery including, but not limited to the following surgical types:

    • Abdominal surgery
    • Orthopedic surgery
    • Spine surgery
    • Genitourinary surgery
  • Patient classified as American Society of Anesthesiologists (ASA class I-III).
  • Female subjects are eligible only if all of the following apply:

    • Not pregnant (subjects of child bearing potential must have a negative beta human chorionic gonadotropin (β-hCG) pregnancy test before surgery);
    • Not lactating;
    • Not planning to become pregnant within the duration of the study;
  • Patients who are expected to have acute pain requiring oral opioid analgesics for at least 48 hours during the post operative period (either inpatient or outpatient).
  • Patient must report a categorical pain rating of moderate to severe on a scale of none, mild, moderate, or severe prior to randomization.
  • Patients who are willing and capable of understanding and cooperating with the requirements of the study.
  • Patients able to understand and communicate in English.

Exclusion Criteria:

  • Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation, safety, or conduct of the study such as but not limited to a history of severe renal or hepatic impairment, severe active hepatic disease, or any other clinically significant medical condition that may preclude safe study participation
  • Patients who have a known severe allergy or hypersensitivity to opioid analgesics, anesthetics, APAP (acetaminophen.)
  • Patients who have a history of intolerance to short term opioid use.
  • Patients who have abused any prescription medication or alcohol within two years before the start of the study.
  • Patients who require an additional scheduled surgical procedure within 48 hours of the surgery.
  • Patients who have a history of seizures, or are currently taking anticonvulsants.
  • Patients who have dysphagia and/or cannot swallow study medication whole.
  • Patient who is unable to adequately communicate with study staff, properly give informed consent, or otherwise comply with study procedures.
  • Patient who has participated in another clinical trial of an investigational drug or device within 30 days of screening visit or is schedule to receive an investigational product while participating in the study.

Post operative Exclusion Criteria at Randomization:

  • Patients who are not awake, not breathing spontaneously, or have a respiratory insufficiency.
  • Patients who are vomiting and not responsive to standard treatment
  • Patients not able to answer questions and follow commands.
  • Patients who have surgical complications that could compromise safety of the subject or confound the results of the study.

Sites / Locations

  • Lotus Clinical Resarch,LLC

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Percocet

Xartemis

Arm Description

Oxycodone/APAP (acetaminophen)

Outcomes

Primary Outcome Measures

Non Inferiority
To demonstrate the non inferiority of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute post operative pain when compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours. The statistical comparison of interest will be the patient global assessment of analgesic effect administered at 48 hours after treatment initiation.

Secondary Outcome Measures

Patient Global Assessment
To assess patient global assessments at 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.

Full Information

First Posted
March 28, 2014
Last Updated
April 6, 2018
Sponsor
Lotus Clinical Research, LLC
Collaborators
Mallinckrodt
search

1. Study Identification

Unique Protocol Identification Number
NCT02101476
Brief Title
An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.
Official Title
A Randomized, Open Label,Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP (Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
October 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lotus Clinical Research, LLC
Collaborators
Mallinckrodt

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the analgesic efficacy of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute moderate to severe post operative pain to generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Operative Pain
Keywords
Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
114 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Percocet
Arm Type
Active Comparator
Arm Description
Oxycodone/APAP (acetaminophen)
Arm Title
Xartemis
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Percocet
Other Intervention Name(s)
Oxycodone/APAP(acetaminophen)
Intervention Description
10mg/650mg
Intervention Type
Drug
Intervention Name(s)
Xartemis
Intervention Description
15mg/650mg
Primary Outcome Measure Information:
Title
Non Inferiority
Description
To demonstrate the non inferiority of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute post operative pain when compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours. The statistical comparison of interest will be the patient global assessment of analgesic effect administered at 48 hours after treatment initiation.
Time Frame
48 Hours
Secondary Outcome Measure Information:
Title
Patient Global Assessment
Description
To assess patient global assessments at 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.
Time Frame
120 Hours
Other Pre-specified Outcome Measures:
Title
Healthcare Professional Global Assessment
Description
To assess healthcare professional global assessments at 48 hours and 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.
Time Frame
48 Hours
Title
Healthcare Professional Global Assessment
Description
To assess healthcare professional global assessments at 48 hours and 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.
Time Frame
120 Hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who provide written informed consent prior to enrollment Male or female and 18 years of age or older. Patients who are scheduled to undergo elective general surgery including, but not limited to the following surgical types: Abdominal surgery Orthopedic surgery Spine surgery Genitourinary surgery Patient classified as American Society of Anesthesiologists (ASA class I-III). Female subjects are eligible only if all of the following apply: Not pregnant (subjects of child bearing potential must have a negative beta human chorionic gonadotropin (β-hCG) pregnancy test before surgery); Not lactating; Not planning to become pregnant within the duration of the study; Patients who are expected to have acute pain requiring oral opioid analgesics for at least 48 hours during the post operative period (either inpatient or outpatient). Patient must report a categorical pain rating of moderate to severe on a scale of none, mild, moderate, or severe prior to randomization. Patients who are willing and capable of understanding and cooperating with the requirements of the study. Patients able to understand and communicate in English. Exclusion Criteria: Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation, safety, or conduct of the study such as but not limited to a history of severe renal or hepatic impairment, severe active hepatic disease, or any other clinically significant medical condition that may preclude safe study participation Patients who have a known severe allergy or hypersensitivity to opioid analgesics, anesthetics, APAP (acetaminophen.) Patients who have a history of intolerance to short term opioid use. Patients who have abused any prescription medication or alcohol within two years before the start of the study. Patients who require an additional scheduled surgical procedure within 48 hours of the surgery. Patients who have a history of seizures, or are currently taking anticonvulsants. Patients who have dysphagia and/or cannot swallow study medication whole. Patient who is unable to adequately communicate with study staff, properly give informed consent, or otherwise comply with study procedures. Patient who has participated in another clinical trial of an investigational drug or device within 30 days of screening visit or is schedule to receive an investigational product while participating in the study. Post operative Exclusion Criteria at Randomization: Patients who are not awake, not breathing spontaneously, or have a respiratory insufficiency. Patients who are vomiting and not responsive to standard treatment Patients not able to answer questions and follow commands. Patients who have surgical complications that could compromise safety of the subject or confound the results of the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil Singla, MD
Organizational Affiliation
Lotus Clinical Research, LLC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lotus Clinical Resarch,LLC
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States

12. IPD Sharing Statement

Learn more about this trial

An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

We'll reach out to this number within 24 hrs